Fitusiran for young boys with hemophilia A or B
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if fitusiran, given as a shot, can help prevent bleeding in boys ages 1 to 12 with severe hemophilia (factor VIII under 1% or factor IX at 2% or lower). It includes boys with or without inhibitors and aims to understand safety and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a boy between 1 and 11 years old.
- Have severe hemophilia A (factor VIII under 1%) or B (factor IX at 2% or lower).
- In the last 3 months, you have been using bypassing agents (if you have inhibitors) or clotting factor concentrates (if you don't have inhibitors) to prevent or treat bleeding.
- Have adequate veins for blood draws.
- Parent or guardian must sign consent, and you may need to give your okay too.
- Not have other bleeding disorders, liver disease, or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called fitusiran to help prevent bleeding episodes in people with severe hemophilia A who are already receiving emicizumab. It may offer an additional treatment option for those with or without inhibitors.
This trial tests a single dose of CSL222, a gene therapy, in adolescent boys with severe or moderately severe hemophilia B. The goal is to see if it can reduce or eliminate the need for regular factor IX infusions.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.